Trial
NCT02591654
MRI and PET to Assess Pembrolizumab Response
Early Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Columbia University
Collaborators
Merck Sharp & Dohme LLC
Condition
Malignant Melanoma, Metastatic
Intervention
Pembrolizumab
Why stopped
Poor enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-12-30